US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Detailed price information for Klotho Neurosciences Inc (KLTO-Q) from The Globe and Mail including charting and trades.

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Detailed price information for Klotho Neurosciences Inc (KLTO-Q) from The Globe and Mail including charting and trades.

Klotho Neurosciences moves forward with manufacturing gene therapy to treat amyotrophic lateral sclerosis: New York Tuesday, July 1, 2025, 15:00 Hrs [IST] Klotho Neurosciences, In ...